Clindamycin hydrochloride NEW
| Price | $48 |
| Package | 100mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Clindamycin hydrochloride | CAS No.: 21462-39-5 |
| Purity: 99.84% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Clindamycin hydrochloride |
| Description | Clindamycin hydrochloride (Clinimycin HCl) inhibits protein synthesis by acting on the 50S ribosomal. It is the hydrochloride salt form of clindamycin, a semi-synthetic, chlorinated broad-spectrum antibiotic produced by chemical modification of lincomycin. Clindamycin hydrochloride(Clinimycin HCl) is used as a solid in capsules. |
| Kinase Assay | In vitro potency assays: After RO4929097 is used, the Aβ peptides are measured by ECL assays using a variety of anti-Aβ antibodies and an Origen 1.5 Analyzer. The 4 g8 murine mAb binds an epitope in the Aβ peptide (within amino acids 18–21) that is immediately distal to the α-secretase cleavage site. The G2–10 murine mAb binds the C terminus that is exposed after γ-secretase-mediated cleavage to generate amino acid 40 of the Aβ40 peptide. The FCA3542 rabbit antibody binds the C terminus that is exposed after γ-secretase-mediated cleavage to generate amino acid 42 of the Aβ42 peptide. The 4 g8 mAb is biotinylated with biotin-LC-sulfo-N-hydroxysuccinimide-ester. The G2–10 and FCA3542 antibodies are ruthenylated with TAG-N-hydroxysuccinimide ester. Aβ(x-40) is detected with biotinylated 4 g8 and ruthenylated G2–10. Aβ(x-42) is detected with biotinylated 4 g8 and ruthenylated FCA3542. |
| In vitro | Clindamycin is a classical inhibitor of bacterial protein synthesis which binds to the 23S ribosomal RNA of the 50S ribosomal subunit. [1] |
| In vivo | Clindamycin hydrochloride is rapidly absorbed orally in dogs, exhibiting a mean absorption time (MAT) of 0.87 hours and a bioavailability of 72.55%. It shows a total clearance (CL) rate post intravenous (IV) and oral administration of 0.503 and 0.458 L/h/kg respectively, and reaches a steady-state volume of distribution (IV) of 2.48 L/kg, indicating extensive distribution throughout the body's fluids and tissues. Serum concentrations of clindamycin remain above 0.5 μg/mL for approximately 10 hours after both IV and oral administration. [1] Additionally, it significantly reduces oral malodor, dental plaque, dental calculus, and gingival bleeding in dogs over a period of 42 days. [2] At a dosage of 2.5 mg/lb following ultrasonic scaling, root planing, and polishing (USRP), clindamycin significantly impacts plaque and pocket depth related to periodontal disease, though not gingivitis. [3] Furthermore, it achieves a complete remission ratio of 71.4% (15/21) in dogs with canine superficial bacterial pyoderma within 14 to 28 days. [4] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.33 mM), Sonication is recommended. 10% DMSO+90% Saline : 10 mg/mL (21.67 mM), Solution. DMSO : 250 mg/mL (541.78 mM), Sonication is recommended. |
| Keywords | Inhibitor | inhibit | Clindamycin hydrochloride | Clindamycin | Bacterial | Antibiotic |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Approved Drug Library | ReFRAME Related Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | FDA-Approved Drug Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | NMPA-Approved Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-06-22 | ||
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-16 | ||
| $1.00 |
VIP8Y
|
.GZ HONESTCHEM CO.,LTD
|
2026-06-15 | |
|
VIP3Y
|
Hangzhou Hyper Chemicals Limited
|
2026-05-29 | ||
| $145.00 |
VIP6Y
|
Baoji Guokang Healthchem Co., Ltd.
|
2026-05-15 | |
| $10.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2026-03-20 | ||
|
VIP3Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2026-03-12 | ||
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-12-01 | ||
| $10.00 |
VIP3Y
|
Henan Fengda Chemical Co., Ltd
|
2025-09-25 | |
| $50.00 |
Hebei Yanxi Chemical Co., Ltd.
|
2025-06-20 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY